WILLIAMS AND JENSEN, PLLC for PFIZER
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Drug safety and drug counterfeiting; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Health care reform including H.R. 3200, America's Affordable Health Choices Act; Affordable Health Choices Act; America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; and H.R. 3590, Patient Protection and Affordable Care Act; Senator Kennedy cancer legislation; Prescription drug advertising; and Federal preemption for prescription drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| REBECCA ANDERSON | — |
| JENNY DIJAMES | — |
| DENIS DWYER New | — |
| JACK STEVEN HART | — |
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| KARINA LYNCH | — |
| GEORGE OLSEN | — |
| PATRICK PETTEY | — |
| ANTHONY J RODA | — |
| JOYCE A ROGERS | — |
Labor Issues/Antitrust/Workplace LBR
Wyeth acquisition
| Lobbyist | Covered position, as disclosed |
|---|---|
| REBECCA ANDERSON | — |
| JENNY DIJAMES | — |
| JACK STEVEN HART | — |
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| KARINA LYNCH | — |
| MELINDA M MAXFIELD | — |
| GEORGE OLSEN | — |
| PATRICK PETTEY | — |
| ANTHONY J RODA | — |
| JOYCE A ROGERS | — |
Medicare/Medicaid MMM
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; and Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNY DIJAMES | — |
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| KARINA LYNCH | — |
| MELINDA M MAXFIELD | — |
| GEORGE OLSEN | — |
| JOYCE A ROGERS | — |
Taxation/Internal Revenue Code TAX
Tax issues affecting the pharmaceutical industry including international tax
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| KARINA LYNCH | — |
| GEORGE OLSEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.